RnR Market Research, a company offering market research reports on fields that include healthcare, pharmaceutical, technology, energy, and industry, recently publicized a new report on the epidemiology of multiple sclerosis (MS) and a forecast of its therapeutic market value. The report is entitled “EpiCast Report: Multiple Sclerosis – Epidemiology Forecast to 2024”.
The estimated incidence and prevalence of MS is known to vary greatly between countries, even within countries, and according to age and sex. The MS EpiCast Report was developed by GlobalData, a company offering insights into the global energy and healthcare markets, and written by expert epidemiologists with Master and PhD degrees.
According to a press release, the report offers a summary of the risk factors, comorbidities, and global trends associated with MS, focusing especially on the 10 major MS markets: United States, Canada, United Kingdom, France, Germany, Spain, Italy, China, Japan, and India. The report contains a 10-year epidemiological forecast for MS (2014–2024) in terms of disease prevalence and incidence, taking into account the age and sex of patients in each of the markets mentioned. It also provides an overview of the three main types of the disease: relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS).
Remarkably, according to the report, the value of the MS therapeutics market in the 10 countries analyzed is expected to grow from $17.2 billion in 2014 to around $20 billion in 2024. This growth will be mainly driven by the continued uptake of high-quality products and the increase in treatment rates induced by the availability of new therapies.
In terms of MS cases, the authors state in the report that in 2014 there were a total of 909,398 individuals diagnosed with MS in the 10 countries considered, and predict that by 2024, the number of diagnosed prevalent MS cases will reach 942,567. Regarding newly diagnosed cases (incident cases), in 2014 a total of 60,535 were reported in the 10 countries, while the epidemiologist forecast expects that this number will increase to 62,635 cases in 2024. These estimates were based on country-specific studies published in peer-reviewed journals, and using similar methodologies to compare MS prevalence and incidence.
RnR Market Research has the report available for purchase in the following link.